Drug intelligence / Profile preview

ADVC-004

Development stage: Unknown
Lead developer: Advancell
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ADVC-004 is a therapeutic radiopharmaceutical under development by AdvanCell Isotopes. It is in the discovery phase and is being investigated primarily for the treatment of neoplasms, with a specific focus on prostatic cancer (prostate cancer). As a radiopharmaceutical, it likely delivers targeted radiation to tumor cells, but detailed information about its mechanism of action or molecular target has not been disclosed publicly. The drug's development status remains at the preclinical or early research stage as of March 2025[1].

Beyond the preview

Go deeper on ADVC-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADVC-004.

Explore the full profile